Christopher Fenimore
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christopher Fenimore
Christopher Fenimore is recorded as CFO at Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. reported in an 8-K filed January 31, 2024 that Christopher Fenimore was appointed Senior Vice President, Finance and Chief Financial Officer, effective February 5, 2024. The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $6,985,364 for Christopher Fenimore in fiscal 2025, including a base salary of $725,000. Disclosed compensation is on record for 2 fiscal years. Christopher Fenimore has spoken on 1 earnings call across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on October 28, 2025.
“On January 26, 2024, based on a previously disclosed Chief Financial Officer succession plan, Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer to succeed the current Chief Financial Officer, Robert E. Landry, who is retiring.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Regeneron Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- George D. Yancopoulos, M.D., Ph.D. Chairman
- Leonard S. Schleifer, M.D., Ph.D. Chairman
- Joseph J. LaRosa General Counsel
- Christine A. Poon Board Member
- Craig B. Thompson, M.D. Board Member
- David P. Schenkein Board Member
- David P. Schenkein, M.D. Board Member
- Huda Y. Zoghbi, M.D. Board Member
- Joseph L. Goldstein, M.D. Board Member
- Kathryn Guarini Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, Finance and Chief Financial Officer6 | $725,000 | $6,985,364 |
| 2024 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, Finance and Chief Financial Officer | $660,000 | $6,268,252 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.